NCT02106585View on ClinicalTrials.gov

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Diabetes Mellitus
Interventions
DRUG

JTT-251 or Placebo

Subjects will receive JTT-251 or Placebo

Trial Locations (1)

Unknown

Orlando

Sponsors

Lead Sponsor

Akros Pharma Inc.
All Listed Sponsors
lead

Akros Pharma Inc.

INDUSTRY

NCT02106585 - Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects | Biotech Hunter | Biotech Hunter